XRTX Stock Analysis: Buy, Sell, or Hold?
XRTX - XORTX Therapeutics Inc. Common Stock
$2.13
0.10 (4.93%)
▲
5d:
+0.47%
30d:
+1.19%
90d:
-19.62%
WAIT
LOW Confidence
Analysis Updated: Aug 7, 2026 12:00 AM ET
Earnings: Aug 13, 2026
3d
Get Alerted When XRTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: XRTX shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: XRTX shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$2.62
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$1.63
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 1.7x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: XRTX is currently trading at $2.13, which is considered extended relative to its 30-day fair value range of $2.02 to $2.12. From a valuation perspective, the stock is trading at a premium (Forward PE: 1.9) compared to its historical average (1.7). At these levels, the market is pricing in 4.1% annual earnings growth.
Technical Outlook: Technically, XRTX is in a uptrend. Immediate support is located at $1.95, while resistance sits at $2.27. The stock is showing strong short-term momentum, up 4.9% recently.
Market Sentiment: XRTX scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $14.04 (+559.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, XRTX is in a uptrend. Immediate support is located at $1.95, while resistance sits at $2.27. The stock is showing strong short-term momentum, up 4.9% recently.
Market Sentiment: XRTX scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $14.04 (+559.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$2.02 -
$2.12
Company Quality Score
41/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
36.7%
All Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.9%)
- BULLISH: Trading 559.0% below Wall St target ($14.04)
- BULLISH: Expecting earnings turnaround to 4.1% growth with None% revenue growth
- WARNING: Composite score 41/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$2.02 -
$2.12
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$1.95
Resistance Level
$2.27
Current Trend
Uptrend
Technical data as of
Aug 7, 2026
Fundamental Context
Forward P/E (Next Year Est.)
1.93
Wall Street Target
$14.04
(+559.0%)
Earnings Growth (YoY)
-97.2%
Valuation Premium vs History
+4.1% premium
PE vs Historical
1.9 vs 1.7
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+4.1%
(market-implied from PE analysis)
1-Year Target
$2.22
(+4%)
2-Year Target
$2.31
(+8%)
3-Year Target
$2.40
(+13%)
3-Yr Target (if PE normalizes)
(PE: 2→2)
PE COMPRESSION
$2.11
(-1%)
Earnings growth offset by PE compression
Share & Embed Analysis
Last updated: August 09, 2026 9:31 AM ET
Data refreshes hourly during market hours. Next update: 10:31 AM
Data refreshes hourly during market hours. Next update: 10:31 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is XRTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 47 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$282 | 63 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$106 | 49 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$125 | 51 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$33 | 43 HOLD |
